Trial reportJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2011
Safety of regadenoson in patients with end-stage liver disease.
Trial report in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Pooled it
- Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Trial
- Cardiac imaging for the assessment of patients being evaluated for liver transplantation.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Review
- Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Review
- ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Article
- Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2015Review
- Cardiac imaging for the assessment of patients being evaluated for kidney or liver transplantation.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2015Review
- Editorial: Regadenoson: An adenosine AJournal of cardiology cases · 2014Article
- Safety and tolerability of regadenoson CMR.European heart journal. Cardiovascular Imaging · 2014Article
- Regadenoson: a focused update.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2013Review
- Prevalence and significance of electrocardiographic changes and side effect profile of regadenoson compared with adenosine during myocardial perfusion imaging.Journal of cardiovascular disease research · 2013Article
- Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.European journal of nuclear medicine and molecular imaging · 2013Article
- Patient-centered imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2012Article
- Selective adenosine agonists and myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2012Review
- Nuclear cardiology: 2014 innovations and developments.Methodist DeBakey cardiovascular journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegadenoson is a selective A(2A) receptor agonist that is used for vasodilator stress myocardial perfusion imaging (MPI). Since the drug is partially metabolized by the liver, its safety in patients with end-stage liver disease (ESLD) needs to be determined. METHODS AND
resultsWe studied 168 consecutive patients with ESLD who had regadenoson stress gated single photon emission computed tomography MPI between January 2008 and March 2010 before planned orthotopic liver transplantation and compared the hemodynamic responses and safety profile to 168 control patients. There were 72 women (43%) in ESLD versus 87 (52%) in the control group (P = .1). The patients with ESLD were younger (58 ± 7 vs 62 ± 12 years, P = .0002), but more likely to be Caucasians (P = .002). The MPI images were normal in 161 patients (96%) in each group. The left ventricular ejection fraction was 72 ± 10% in ESLD and 66 ± 11% in the control patients (P = .0001). The heart rate increase in response to regadenoson was lower in patients with ESLD than in the control group (16 ± 11 vs 23 ± 16 bpm, P = .0001), but the changes in systolic and diastolic blood pressures were similar (-9 ± 12 vs -11 ± 14 mmHg and -6 ± 8 vs -7 ± 10 mmHg, respectively, P = NS). There were no deaths or medication-related adverse events that required hospitalization in either group within 30 days of the study.
conclusionThis is the first study to document the tolerability and safety profile of regadenoson in patients with ESLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.